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CHAPTER I 
 
INTRODUCTION 
 
Part A: Cancer 
According to the American Cancer Society, an American male has a one in two 
chance of being diagnosed with cancer in his life time and a female has a one in three 
chance.  Fortunately, the five-year survival rate for Americans has risen approximately to 
66% from 1996 to 2003, up from 53% for 1984 to 1986.  For 2008, the American Cancer 
Society estimates that 1.4 million Americans will be diagnosed with a new case of cancer.  
Despite the increase in survival rate, 565,000 Americans will still die of cancer this year.
1
  
This number of yearly deaths related to cancer in the United States is nearly equivalent to 
the population of Nashville, TN.
2
  Cancer deaths are the second leading cause of death in 
America, exceeded only by heart disease.
1
  We must study and understand the facets of 
cancer in order to devise prevention and treatment strategies.  
Cancer is the unregulated growth and spread of cells in the body and is believed 
to be initiated at the genetic level by the accumulation of mutations in the DNA on the 
cellular level.  These mutations seem to be centered in two different, but related, sets of 
genes.  These genes are the proto-oncogenes and the tumor suppressor genes.
 3
  In general, 
proto-oncogenes are involved in cell growth while tumor suppressor genes inhibit cell 
growth.  Research indicates that cancer is dependent on these two classes of genes, which 
can be grouped into two different areas of concentration in the cell, in order to obtain its 
proliferation.
3,4
  The first site is intracellular activity, which can be sub-categorized into 
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agonist-induced signal transduction, DNA replication and repair, cell cycle control, and 
cell fate (survival, differentiation, senescence, and apoptosis). The second site is cell 
surface and extracellular functions, such as adhesion to molecules, proteases, and 
angiogenesis (formation of new blood vessels).
4
  In order to understand some of these 
gene sites, we will briefly explore a few of them. 
Cell cycle control is the ability of the cell to determine if the cell should pass 
through to the next stage of the cycle.  The stages are divided into four distinct phases: 
gap 1 (G1), synthesis (S), gap 2 (G2), and mitosis (M) (Figure 1).  G1 is characterized by 
growth of the cell size and preparations for DNA replications.  S-phase replicates DNA, 
G2 prepares the cell for mitosis, and M is the division of the parent cell into two daughter 
cells.  The gate keepers between the various phases are cyclins and cyclin-dependent 
kinases (CDKs).  If both are not working in conjunction with each other, the cell cannot 
proceed to the next phase, and cell division is arrested.
3 
 
 
Figure 1: Cell cycle 
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Apoptosis is the programmed death of a cell.  If for some reason a cell has a 
problem that cannot be corrected, the cell can initiate a series of events that lead to 
apoptosis.  Such problems may be the injury of chromosomal DNA or disruptions to 
tumor suppressor genes.  While cell “suicide” may seem extreme, the potential threat 
posed by a cancer cells survival is far worse for the survival of the organism.
3
 
Cells have been found to have a limited set of divisions that can occur, 
somewhere in the neighborhood of 55 divisions.  After such time, the cells seem to stop 
dividing and are considered senescent.  However, cells that have a slight mutation in the 
retinoblastoma (RB) or p53 gene could continue to replicate.  After a period of time, the 
surviving cells would reach a second state, crisis, where they would die; although, a few 
will also survive this stage and become immortal, allowing for indefinite replication of 
the cell.
3
  Given these multiple deterrents to cancer, it is understandable that years of 
accumulations of mutations could lead cancer to occur in normal, healthy humans.  The 
question is, if mutations are the cause of cancer, then what causes the mutations?  
Mutations to the DNA of a cell can occur from exogenous and endogenous 
sources.  Endogenous sources have been found to be due to inherited mutations, 
hormones, immune conditions, and mutations that occur from metabolism.  Exogenous 
sources have been found to be such things as tobacco, environmental or occupational 
exposure to chemicals, radiation, infectious organisms, and even diet.
5
  However, 
Western industrialized countries can attribute over 80% of cancer to exogenous sources, 
with diet and tobacco accounting for nearly 65% of those cases.
6
  With such a high 
degree of mutations being linked to exogenous sources, it has become imperative that the 
research community look beyond cancer treatment and focus on the processes which lead 
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to the formation of cancer. Given that exogenous sources may account for the majority of 
cancer cases, this area shall be explored furthered.   
In order to understand the complex nature of exogenous exposure to carcinogens, 
one must understand that each person has a different susceptibility to carcinogens.  
Factors that affect ones susceptibility are gender, ethnicity, diet, age, and health condition.  
Given all these factors, it is no wonder that proving a specific compound as carcinogenic 
is such a daunting task.  A list of selected carcinogens is provided with the cancer they 
are known to induce in Table 1.  It is of note that metabolic activation (also referred to as 
xenobiotic metabolism) is required for many known and suspected chemical carcinogens.  
This was discovered when xenobiotic metabolism of carcinogens was shown to parallel 
the chemical reactivity toward cellular macromolecules.
7 
 
Table 1: Selected Human Chemical Carcinogens
8,9 
 
Compounds Main Sources/ Uses Target Organs/ Cancer Type 
Anticancer Drugs   
Melphalan Chemotherapy Leukemia 
Thiotepa Chemotherapy (no longer in use) Leukemia 
Aromatic Amines/ Amides   
2-Napthylamine Dyes; antioxidant (no longer in use) Bladder 
4-Aminobiphenyl Dyes; antioxidant (no longer in use); 
Research tool 
Bladder 
Metals (and Inorganics)   
Arsenic Natural ores; alloys; pharmaceutical 
agent 
Skin, Lung, Liver 
Cadmium Natural ores; pigments; batteries; 
ceramics 
Lung, Prostate, Kidney 
Nickel Natural ores; alloys; electrodes; 
catalyst 
Lung, Nasal Cavity 
Olefins   
Ethylene oxide Glycol and polyester production; 
sterilization 
Leukemia, Lymphoma 
Vinyl Chloride  Plastics; co-polymers Liver (angiosarcoma) 
Trichloroethylene Degreasing operations; adhesives; 
lubricants 
Liver, Kidney 
Paraffines/ Ethers   
Bis(chloromethyl)ether Technical application (rarely used) Lung 
Mustard Gas (sulphur mustard) Chemical warfare in WWI; research Lung 
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 For many chemical carcinogens, such as polycyclic aromatic hydrocarbons and 
aromatic amines, xenobiotic metabolism is required in order to form a short-lived 
electrophilic compound (often referred to as the “ultimate carcinogen”), which covalently 
modifies DNA and causes the subsequent carcinogenic effect.
10,11
  A plethora of enzymes 
carry out this metabolic action, such as the cytochrome P450s, glutathione S-transferases, 
and sulfonyltransferases.  As a result, oxidizing and conjugating enzymes can activate 
carcinogens that modify DNA.
10
  However, the fact that a chemical compound, or its 
metabolite, can modify DNA does not prove that it is a carcinogen as other factors play a 
role.  These other factors include the extent of DNA adduction, the stability of the adduct, 
and the repair rate of the adduct.  The modification of DNA by a carcinogen can depend 
on the DNA sequence and the reactivity of the carcinogen to DNA.
12
  But as noted above, 
DNA adducts can be repaired. 
 Chemical carcinogens have been found not to react with DNA randomly; rather, 
carcinogens react with certain areas of DNA and nucleotides with higher frequencies.   
Sequence dependence has been observed to be of importance, with areas where DNA is 
prone to adduction known as hot spots.  Two well known hotspots for mutation are a run 
of G’s (GGGGG) and a dinucleotide repeat of alternating G’s and C’s (GCGCGC).  
These hotspots were found with reactive forms of acridines and induced frameshift 
mutations.
13,14
  The reaction of DNA with a chemical carcinogen has been proposed to be 
one of the earliest steps in the initiation of cancer.
15
  Fortunately, nature has developed 
mechanisms that recognize and repair damaged DNA, albeit with vastly different 
efficiencies.  Repair of modified DNA can be accomplished by such repair mechanisms 
as mismatch repair (MMR), base excision repair (BER), and nucleotide excision repair 
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(NER).
16
  However, if these adducts are not repaired, a buildup of these modifications 
can lead to mutations, of which the outcome may lead to numerous alterations, such as 
the switching on or off of genes, irregular protein expression, or alterations in cell cycle 
control.
15
 
 In order for cancer to appear, a set of events must happen; these events include 
adduction of DNA and mutation of specific genes.  The way the adduct works is by 
reacting with DNA and avoiding repair enzymes.  Here, the adduct is incorrectly 
replicated by  a DNA polymerase leading to miscoding errors, i.e. mispairing, deletion, 
translocation.
17
  It is also possible for spontaneous mutations from base substitution or 
frameshift mutation to occur.  These miscoding events must avoid repair, but they must 
also not cause apoptosis.  If there are too many mutations or if the mutations are in 
critical genes, apoptosis can be activated, and the cell does not proceed to a cancerous 
state.  This series of events are summed up in Figure 2.  As stated above, the mutations 
must occur in two sets of genes in order to cause cancer, proto-oncogenes and the tumor 
suppressor genes.  In the end, multiple mutations are needed in these two areas to cause 
cancer.
18
 
 
7 
 
 
Figure 2: Chemical Carcinogen Route to Cancer 
 
Part B: Translesion Synthesis (TLS) 
As mentioned above, mutations may be caused by DNA polymerases.  
Polymerases are enzymes that replicate duplex DNA into two new duplexes; each duplex 
consists of one of the original strands and one newly replicated strand, a process better 
known as semiconservative replication.  In order for a cell to be able to pass on its genes, 
the ability to replicate DNA becomes important.  These replicative enzymes have 
extremely high fidelity, which is the accuracy of the replication, and high processivity, 
which allows for multiple rounds of catalysis with the enzyme before the enzyme 
disassociates from the DNA.
19
  Mutations can arise when a DNA polymerase 
misincorporates across from an adducted base or when slippage occurs.  DNA 
8 
 
polymerases can also spontaneously incorporate the wrong base, thus causing replication 
errors.
20
 
 As mentioned previously, a type of replication error of interest is frameshift 
mutation.  Frameshift mutations are caused by the insertion or deletion of bases in a given 
sequence.  By inserting, or deleting one or two bases, the reading frame is shifted and 
thus can lead to the change in translation of the genetic code.  These mutations can be 
classified by the direction and number of bases that affect the sequence.  The insertion of 
a single base is known as a +1 frameshift; while, the deletion of two bases is known as a 
-2 frameshift.  A model for frameshift mutation that is well accepted is the Streisinger 
slippage model.   The model proposes that the misalignment of the primer and template 
leads to a local bulging of the DNA during replication.  Bulging is where DNA bases are 
extruded outside of the normal double helix.  It is through this bulging that misalignment 
can occur and potentially lead to mutations.
21,22
  It is hypothesized that DNA adducts can 
stabilize the slipped mutagenic (bulged) intermediate and can thereby promote frameshift 
mutations.  An example of this is the aromatic amide, N-acetylaminoflourene (AFF), 
which can be seen in Figure 3.
22 
 
 
Figure 3: -2 Frameshift Mutation with AAF 
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Most replicative DNA polymerases share three common features: fingers, thumb 
and palm domains, which can be seen in Figure 4.  The fingers interact with the 
incoming nucleoside triphosphate and the template base.  As for the thumb, it positions 
the DNA and it also plays a role in the process and translocation associated with the 
enzyme.  The palm catalyzes the phosphoryl transfer reaction.
23
  Even though they have 
these similar regions, the kinetics, mechanism, fidelity, and processivity differ greatly 
between the different polymerases.
24 
 
 
Figure 4: Regions of DNA Polymerases
25 
 
 Depending on the DNA polymerase, mis-insertion and local environment of the 
sequence, error rates for single base nucleotide substitution vary from 10
-3
 to >10
-6
.
26
  
DNA adducts can inhibit DNA replication and cause the replication fork to be halted.  
Recent data suggests that a gap is left where the replicative polymerases cannot replicate 
and then replication is carried on past the adduct.
27
  A class of DNA polymerases has 
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recently been discovered that are able to conduct TLS and replicate through damaged 
DNA.  These enzymes are largely members of the Y-family DNA polymerases. 
In order to understand the complexity of TLS (of which much is still unknown) a 
simplified figure has been provided to walk through the steps of TLS (Figure 5).  When 
an adduct is detected, two proteins are recruited, Rad18 and Rad6, and they signal for the 
cleavage of USP1, which is involved in the removal of ubiquitin from the proliferating 
cell nuclear antigen (PCNA), and allows for ubiquitination of PCNA.  After PCNA has 
been ubiquitinated, the binding constants of the TLS polymerases are increased enough to 
allow for replacement of the higher binding, high fidelity polymerases (i.e., pol δ) with a 
Y-family polymerase (i.e., pol η).  Translesion synthesis is carried out past the adduct, 
after which the higher fidelity polymerases are allowed to carry out the rest of the 
synthesis.
27 
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Figure 5: Model for TLS
27 
 
 
 In contrast to replicative DNA polymerases, which can synthesize DNA with 
higher efficiency and accuracy, the Y-family DNA polymerases have a significantly 
higher error rate.  The lower accuracy can be attributed to the fact that many of these TLS 
polymerases do not have exonuclease activity, which acts as a proofreader for the 
polymerase.  In order to make up for this lack of an exonuclease, these polymerases have 
a little finger domain that helps facilitate the association of DNA, catalytic efficiency, 
and interactions with auxiliary factors.
28
 
 Given the complexity of TLS shown above, which is based on the synthesis in 
eukaryotes, simpler models have been devised in order to study the replication of these 
polymerases.  Archaea have been studied for their mechanism of replication of DNA, and 
are believed to be similar to human replication, but at a simpler level.
29,30
  The 
12 
 
advantages of using the archaea  system is that they are structurally simpler, and there are 
proteins that are used in the analogous synthesis, which are structurally close to 
eukaryotes.
31
  Sulfolobus solfataricus P2 has a polymerase known as DNA polymerase 
IV (Dpo4), which has been used as a model of the eukaryote polymerase η, although it is 
more closely reflected to pol κ.32  Given the low fidelity and processivity, Dpo4 shows all 
the classical signs of Y-family DNA polymerases, including the lack of an exonuclease 
domain.  Because of these characteristics, Dpo4 has helped in the study of replication 
with regards to mutation. 
 Like eukaryotes, bacteria are susceptible to modification of their DNA.  One 
highly conserved protein is the Klenow fragment of Escherichia coli polymerase I.  
Klenow fragment has two enzymatic activities, the polymerase and the exonuclease.  The 
polymerase activity works in the 5’→3’ direction, while the exonuclease works in the 
3’→5’ direction, where the mis-incorporated nucleotides are edited.33  A widely used 
form of the Klenow fragment lacks a functional exonuclease domain (Kf¯).  Although 
removing the function of the exonuclease can alter the overall base substitution activity 
of the enzyme, it is an attractive model for studies of DNA replication with an adducted 
oligonucleotide.
34
 
 E. coli has another highly conserved protein that is used in TLS, polymerase II 
(pol II).  This prototype of the B-family of polymerases is one of the enzymes in the SOS 
system of bacteria.  The SOS system also includes DNA polymerases II, IV, and V, 
which participates in TLS.  It has been proposed that pol II is the enzyme that catalyzes 
the restart of the synthesis of damaged DNA, along with replication through a myriad of 
different adducts.
35
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 The human Y-family polymerase η is a well studied polymerase.   Pol η is known 
to be of extreme importance for the replication past TT dimers (a product of UV 
radiation), by inserting two A’s opposite the dimer.36  In the genetic disease known as a 
variant form of xeroderma pigmentosum, in which the risk of sunlight induced skin 
cancer is greatly enhanced, the subjects typically are deficient of pol η.37,38  It is believed 
that when pol η is not available, that pol ι can serve as a backup polymerase for T-T 
dimmer bypass.  Pol ι is far less efficient at correctly replicating DNA past TT dimers.39 
 Polymerase ι is a very unique polymerase, in that it is the only polymerase 
believed to use Hoogsteen base pairing for replication.
40
  This gives a good explanation 
for why pol ι replicates through N2 adduct, these compounds affect the N2 position of dG.  
As will be discussed later, pol ι has been studied with the N2 adduct γ-hydroxy-1,N2-
propano-2’-deoxyguanosine (γ-HOPdG).  Another reason for the interest of pol ι is that it 
incorrectly incorporates dGTP opposite A at higher rates than the correct base dTTP. 
41
 
However, after pol ι has inserted a base opposite the adduct, it is very inefficient at 
further extension past the adduct.  Pol ι has been proposed to insert a base opposite the 
lesion and then allows another polymerase, such as pol κ, to carry out the extension.42  
With regard to human health, no known human or mammalian conditions have been 
found that relate to individuals lacking pol ι.43 
 One enzyme that has been implicated in working in conjugation with pol ι is pol κ.   
A hypothesis for this states, “that an important biological function of pol ι is to 
incorporate nucleotides opposite minor-groove DNA adducts of purines and that pol κ is 
to carry out the subsequent extension reaction.”42  Another important correlation made 
with pol κ is that when knock-out cells of pol κ were made, UV light sensitivity was 
14 
 
observed.
44
  Since pol κ is believed not to be the major polymerase involved in the bypass 
of adducts related to UV exposure, it is believed to be involved in NER.  This is due to 
NER deficient cells being susceptible to UV light mutations.   
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CHAPTER II 
 
C8-DEOXYGUANOSINE 2-AMINO-METHYLNAPHTHOL[1,2-
d]IMIDAZOLE ADDUCT 
 
Part A: Introduction 
The heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is one of 
the most potent compounds ever tested in the Ames assay of Salmonella typhimurium, 
having been shown to be 20 fold more mutagenic than aflatoxin B1, and is found to be 
present in ppb to ppm levels in a variety of cooked meats and fish.
1,2,3
  Heterocyclic 
amines (HCA’s) have been known to cause mutations in different organisms.  For 
example, HCA’s have been found to cause frameshift mutations in CG repeat sequences 
in bacteria, while point mutations have largely been found in mammalian cells.
4
  Also 
studied in relationship to IQ was a carbocyclic analogue of IQ, 2-amino-3-
methylnaphtho[1,2-d]imidazole (CCIQ, Figure 6).  CCIQ was found to be more than 5 
orders of magnitude (10
5
) less mutagenic for frameshift than IQ with Ames assays.
4
  The 
difference in mutagenic effects can be deduced by the removal of the nitrogen in blue, 
thus showing the importance of it. 
 
 
Figure 6: Structures of IQ and CCIQ 
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Due to the presence of IQ in the diet of most Americans and its mutagenic 
activity, it is likely that 1 plays a role in the etiology of some cancers.  IQ has been 
studied in rodents and was found to induce tumors of the liver, skin, forestomach, and 
colon, among others.
5
  As mentioned, some mutagenic compounds require activation to 
their final mutagenic form; IQ is one of these compounds.  Activation of IQ occurs 
mostly in the liver, where cytochrome P450 1A2 oxidizes IQ to a hydroxylamine.  N-
Acetyltransferase is involved in the subsequent esterification that gives the N-acetoxy 
ester.  Solvolysis of the N-acetoxy ester generates an aryl nitrenium ion, which is the 
DNA modifying agent (ultimate carcinogen).  The major adduct that is formed from IQ is 
at the C8 position of 2’-deoxyguanosine (dG), while the minor adduct is the N2-dG 
adduct.
6
 
 As mentioned earlier, HCA’s are known to cause frameshift mutations at CG 
repeats.  For this reason, the frameshift prone NarI recognition (G1G2CG3CC) will be 
used.  This sequence is known to be a hotspot for -2 frameshift mutation induced by 
arylamines.
7
 
In previous research from the Rizzo group, 1 was incorporated in at the G1 and G3 
position of the NarI sequence and the in vitro replication was examined with three 
different polymerases: Dpo4, Kf¯, and pol II¯.  Replication by Dpo4 was error prone or 
error free depending on the on the local sequence of the adduct.  When the studies were 
carried out with Kf¯, extension past the G1 adduct was inefficient, but the G3-adducted 
base was extended and resulted in a two-base deletion.  Studies performed with pol II¯ 
showed that the G3-adduct was extended resulting in both a -1 and -2 frameshift products. 
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In contrast to, the G1 adduct was replicated in an error-free manner.  These experiments 
were able to show that the G3-position has a higher rate of deletions.
8 
 
Part B: Experimental 
Unless otherwise noted, all commercially available chemicals were used as 
received.  MADLI-TOF mass spectrometry was performed at the Vanderbilt University 
Mass Spectrometry Resource Center.  3-Hydroxypicolinic acid (HPA) was the matrix, 
and ammonium hydrogen citrate (7 mg/mL) was added to suppress sodium and potassium 
adducts.  The purified DNA polymerases Dpo4, Kf¯, and pol II¯ were obtained from the 
lab of Dr. Guengerich (Vanderbilt University).  dNTP solutions (100mM) were 
purchased from New England BioLabs.  [γ-32P]ATP was purchased from Perkin-Elmer 
(NEN).  The unmodified oligonucleotides and primer nucleotides were purchased from 
Midland Certified Reagents.  All synthesized oligonucleotides and their purification 
would not have been made possible without the help of Dr. Ivan Kozekov and Albena 
Kozekova. 
Synthesis of Oligonucleotides: An Expedite 8909 DNA synthesizer (PerSeptive 
Biosystems) was used to synthesize the adducted nucleotides using a 1 μmol scale of the 
Ultramild line of phosphoramidites (phenoxyacetyl-protected dA, 4-isopropyl-
phenoxyacetyl-protected dG, acetyl-protected dC, and T phosphoramidites).  The solid 
supports were purchased from Glen Research.  Manual coupling of the adduct was used 
to incorporate the adduct into the oligonucleotides, otherwise the manufacturer’s standard 
synthesis protocol was used.  For manual coupling, the column was removed from the 
synthesizer and syringes were placed at each end of the column, one of which contained 
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250-300 μL of the manufacturer’s 1H-tetrazole activator solution and the other contained 
250 μL of the phosphoramidite (11mg, 0.095M in anhydrous methylene chloride).  The 
solutions were drawn through the column (1H-tetrazole first).  This was repeated for 30 
min, with several minutes between sets.  The column was returned to the synthesizer and 
allowed the capping, oxidation and detritylation steps to occur before the remainder of 
the oligonucleotide could be synthesized. 
High Performance Liquid Chromatography (HPLC): Analyses and 
purification was performed using a Beckman HPLC with a UV diode array detector 
(Model 166) that monitored at a wavelength of 254 nm.  The software used with the 
HPLC was 32 Karat (Version 3.1).  The oligonucleotides were purified with a sodium 
phosphate buffer at pH 7.0 (Solvent 1) and methanol (Solvent 2).  The gradient was 
initially at 1% solvent 2 and was then linearly increased over 27.5 min to 35% solvent 2.  
After that time, the gradient was increased to 50% over 2.5 min and then followed by 5 
min isocratic at 50% solvent 2.  Finally, the gradient was brought back to initial 
conditions over a period of 5 min. 
Capillary Gel Electrophoresis (CGE): Analyses of the purified oligonucleotides 
were carried out on a Beckman P/ACE Instrument System 5500 Series, in which the 
oligonucleotide was monitored at a wavelength of 260 nm.  The capillaries used with the 
P/ACE MDQ instrument were 31.2 cm x 100 μm eCAP.  The samples were applied at 10 
kV and were allowed to run at 9 kV.  The manufacturer’s 100-R gel (for ss DNA) was 
used to pack the column using a Tris-borate buffer with 7.0 M urea.  Modified 
oligonucleotides were found to be of >95% purity. 
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Synthesis of 5’-d(ACTC-GC8-CCIQ-GCGCCAATCCTTACGAGCCCCC)-3’ 
Oligonucleotide was purified using the HPLC method to yield 29.2μmol.  MALDI-TOF 
MS (HPA): m/z calcd for (M-H) 8320.5, found 8317.4 
Synthesis of 5’-d(ACTCGGC-GC8-CCIQ-CCAATCCTTACGAGCCCCC)-3’ 
Oligonucleotide was purified using the HPLC method to yield 27.7 μmol.  MALDI-TOF 
MS (HPA): m/z calcd for (M-H) 8320.5, found 8317.7 
Labeling and Annealing of Oligonucleotides: The given primer was labeled at 
the 5’-end by T4 polynucleotide kinase (T4PNK) and buffer (T4PNK buffer), which were 
obtained from New England BioLabs, and [γ-32P]ATP.  One nmol of primer was used 
with 5 μL of T4PNK buffer (10x concentration) and 40 units of the T4PNK enzyme.  [γ-
32P]ATP, with 12.5 μL, was added and the volume adjusted to 50 μL with water.  The 
reaction was allowed to react for one hour at 37 °C and then stopped by placing the 
reaction in a 95 °C bath for 10 min.  The reaction was purified on a Biospin column 
(BioRad).  Annealing a 1:1 molar ratio of the adducted or unadducted template and 
primer was carried out with 50 mM Tris-HCl buffer (pH 7.8) by heating for 5 min at 
95 °C and then allowing for a slow cool down to 30 °C. 
Single Nucleotide Incorporation Assays: The annealed 
32
P-labeled 
oligonucleotides were extended in the presence of a single dNTP.  The dNTPs (2 μL) 
were added to preincubated enzyme/DNA mixtures which brought the total amount of 
solution to 10 μL.  The final concentrations for the assays with Dpo4, Kf- and pol II¯ 
were: 50 mM Tris-HCl, pH 7.8, 100 nM DNA duplex, 48 nM enzyme, 1 mM DTT, 50 μg 
mL
-1
 BSA, 50 mM NaCl, and 5 mM MgCl2.  Dpo4 reactions were run at 37 °C for 30 
min; while Kf¯ and pol II¯ were allowed to react for 15 min at ambient temperature.  The 
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reactions were quenched by 70 μL of a 20 mM EDTA in 95% formamide (v/v) 
containing bromophenol blue and heated for 10 min at 95°C.  Electrophoresis was used to 
separate aliquots (2-5 μL) of the reaction on a denaturing gel containing: 8.0 M urea, 16% 
acrylamide (w/v) (from 19:1 Acrylamide/Bisacrylamide Stabilized Solution, AccuGel, 
National Diagnostics), and 80 mM Tri borate buffer, pH 7.8, with 1 mM EDTA.  A 
PhosphorImager screen (Imaging Screen K, Bio-Rad) was exposed to the gel for a 
minimum of 6 hours.  The screen was imaged using a PhosphorImaging system (Bio-Rad, 
Personal Molecular Imager) and the manufacturer’s Quantity One software, version 4.6.3. 
Full-length Extension Assay: The annealed 
32
P-labeled oligonucleotides were 
extended in the presence of all four dNTPs.  The dNTPs (2 μL) were added to 
preincubated enzyme/DNA mixtures to bring the total amount of solution to 10 μL.  The 
final concentrations for the assays with Dpo4, Kf¯, and poll II were: 50 mM Tris-HCl, 
pH 7.8, 100 nM DNA duplex, 48 nM enzyme, 1 mM DTT, 50 μg BSA mL-1, 50 mM 
NaCl, and 5 mM MgCl2.  Dpo4 reactions were ran at 37 °C for 30 min; while Kf
-
 and pol 
II¯ were allowed to react for 15 min at 23 °C.  The reactions were quenched with 70 μL 
of a 20 mM EDTA in 95% formamide (v/v) containing bromophenol blue and heated for 
10 min at 95°C.  Electrophoresis was used to separate aliquots (2-5 μL) of the reaction on 
a denaturing gel containing: 8.0 M urea, 16% acrylamide (w/v) (from 19:1 
Acrylamide/Bisacrylamide Stabilized Solution, AccuGel, National Diagnostics), and 80 
mM Tri borate buffer, pH 7.8, with 1 mM EDTA.  A PhosphorIamger screen (Imaging 
Screen K, Bio-Rad) was exposed to the gel for a minimum of 6 hours.  The screen was 
imaged using a PhosphorImaging system (Bio-Rad, Personal Molecular Imager) and the 
manufacturer’s Quantity One software, version 4.6.3 
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Part C: Results and Discussion 
 
A: CCIQ 
 Three different oligonucleotides were synthesized, two containing the C8-CCIQ 
adduct at either the G1 or the G3 position of the NarI sequence and one containing no 
modification at all.  Once the oligonucleotides were purified, they were labeled at the 5’ 
end with 
32
P phosphate.  The template was then annealed with the corresponding -1 
primer for single nucleotide incorporation or -4 primer for nucleotide extension.  The 
given sequences were used in order to compare the results obtained by James Stover with 
the C8-IQ adduct.
8
  The two positions tested have significantly different properties.  The 
G1 position of NarI sequence with the C8-IQ adduct has been found to be in a minor 
groove-bound conformation by Feng Wang and Michael P. Stone.
9
  They also found that 
the G3 position of NarI with IQ adopts a base-displaced intercalated conformation.
10
 
 
Klenow Fragment 
  CCIQ was shown to be a significant block to Kf¯.  The polymerase was able to 
incorporate only a negligible amount of dCTP (Figure 7: 1a, 2a), but only at high dCTP 
concentrations.  This was also the case when the adduct was incorporated at both the G1 
and G3 position.  This differed from the IQ results, which showed that Kf¯ could 
incorporate dCTP more efficiently.  We observed incorporation of dCTP with the 
unmodified oligonucleotides, even with the lowest concentration in both oligonucleotides 
(Figure 7: 1b, 2b).   
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Figure 7: Single Nucleotide Incorporation by Kf¯ 
 
The CCIQ modified oligonucleotides were annealed to -4 primers, and extension 
by Kf¯ in the presence of all four dNTPs was also examined.  The polymerase was 
determined to be unable to extend the primer up to the adduct but insertion opposite the 
CCIQ was completely inhibited (Figure 8: 1a, 2a).  This result is consistent with the 
results observed for the single nucleotide incorporation studies, where Kf¯ was unable to 
incorporate a base opposite the adduct.  On the other hand, Kf¯ was able to fully extend 
the primer opposite the unmodified template in both cases (Figure 8: 1b, 2b).  When 
CCIQ is compared to IQ, these results show that CCIQ is a complete block to replication 
by Kf¯, but the IQ adduct is bypassed and gives a modest amount of full extension 
products and -2 deletion product at the G3 position.
8
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Figure 8: Nucleotide Extension by Kf¯ 
 
Polymerase II 
CCIQ was also found to be a complete block for pol II¯ at the G1 position of the 
NarI sequence (Figure 9: 1a).  Pol II¯ efficiently incorporated dCTP opposite an 
unmodified G (Figure 9: 1b).  At the G3 position, pol II¯ incorporated both dCTP and 
dGTP opposite CCIQ (Figure 9: 2a).  This differed greatly from results obtained with the 
C8-IQ adduct, where pol II¯ was only able to incorporate dGTP opposite the G1 position 
and was able to insert dCTP and dGTP opposite the G3 position, with dGTP incorporated 
more efficiently.
8
  The unmodified oligonucleotide was able to incorporate only the 
correct base, dCTP (Figure 9: 2b).  In summary, misincorporation was observed for 
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CCIQ adduct at the G3 position, which is similar to that of the C8-IQ adduct, though the 
dNTP insertion appears to be less efficient.  
 
 
Figure 9: Single Nucleotide Incorporation by Pol II¯ 
 
 The results obtained from pol II¯ for primer extension are consistent with the 
single nucleotide incorporations (Figure 10).  Pol II¯ was not able to extend the primer 
past the CCIQ adduct at the G1 position (Figure 10: 1a), suggesting that the C8-CCIQ 
adduct is a block to replication.  As was the case with the CCIQ adduct at the G3 position 
(Figure 10: 2a), with a running start pol II¯ was able to incorporate up to the adduct, but 
not across from or past the adduct.  This differs from the single nucleotide incorporation 
reactions because slight incorporation at the higher concentrations of dCTP and dGTP 
was observed.  The reactions were run again in which both dNTPs and time were 
increased. The results confirmed the full extension reactions in which the CCIQ adduct at 
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(X = CCIQ3) 
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the G3 position is a block to replication (Appendix A).  Unlike CCIQ, pol II¯ was able to 
replicate the full length extended product opposite the C8-IQ adduct, with error-free 
bypass seen for the G1 position and -1 and -2 products seen for the G3 position.
8
  Pol II¯, 
like Kf¯, was able to carry out full length extension for the unmodified oligonucleotides 
(Figure 10: 1b, 2b). 
 
 
 
Figure 10: Nucleotide Extension by Pol II 
 
Dpo4 
For the polymerase Dpo4, efficient incorporation of dCTP opposite the C8-CCIQ 
adduct at the G1 position was observed (Figure 11: 1a, 1b).  At the G3 position, Dpo4 
was able to incorporate dCTP opposite the C8-CCIQ adduct but with less efficiency than 
when the adduct was at the G1 position (Figure 11: 2a, 2b).  These results were also 
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observed in the studies with C8-IQ adduct, with the difference being that C8-CCIQ 
adduct at the G3 position did not misincorporate T.
8
   
 
 
Figure 11: Single Nucleotide Incorporation by Dpo4 
 
  In the full extension reactions with the recessed primers, it was observed that 
Dpo4 was able to incorporate opposite the C8-CCIQ adduct but there was a pause just 
before the adduct, and extension past the adduct was not observed for either position 
(Figure 12: 1a, 2a).  The incorporation opposite the adduct is in accordance with the 
results from our single nucleotide incorporation studies.  Once more, like the other 
polymerases, the unmodified oligonucleotide was fully extended by Dpo4 (Figure 12: 1b, 
2b).  In contrast to the present results, Dpo4 was able to extend the C8-IQ adduct at the 
G3 position to give -1 and -2 deletion products.
8
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Figure 12: Nucleotide Extension by Dpo4 
 
Part D: Conclusion 
The dietary mutagen IQ has been well studied in the Rizzo lab, as well as others, 
but the analogue CCIQ has not been.  The C8-CCIQ adduct was placed in a sequence 
containing the frameshift prone NarI sequence that was previously studied with the C8-
IQ adduct.  Two positions were studied in the NarI sequence, the G1 and G3 positions.  
Replicative studies were then carried out with recessed primers for both single nucleotide 
incorporation and full length extension.  The three polymerases used for the in vitro 
replication studies were Kf¯, pol II¯, and Dpo4.  
 Single nucleotide incorporation assays showed that Kf¯ was blocked by the C8-
CCIQ adduct at both positions.  Pol II¯ was also blocked when the C8-CCIQ adduct at 
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the G1 position; but pol II¯ was able to incorporate both a dCTP and dGTP with 
reasonable efficiencies opposite the adduct when at the G3 position of the NarI sequence.  
Unlike the other polymerases, Dpo4 was able to insert opposite the CCIQ adduct at both 
positions of the NarI sequence and no mis-incorporation was seen. 
 Full-length extension reactions were also examined for the C8-CCIQ adduct at 
both positions of the NarI sequences with the three polymerases.  At the G1 and G3 
positions, the C8-CCIQ adduct blocked insertion opposite the adduct and extension past 
the adducts was fully inhibited with Kf¯ and pol II¯.  These results are in line with the 
results obtained by the single nucleotide incorporation reactions, except for the G3 
position of the C8-CCIQ adduct with pol II¯.  We expected to see at least minor 
incorporation opposite the adduct.  Increasing the concentration of dNTPs and length of 
the reaction time resulted in low levels of incorporation opposite the adduct, but no 
further extension (Appendix A).  Unlike these two polymerases, Dpo4 was able to 
incorporate opposite C8-CCIQ adduct at both positions but extension past the adduct was 
blocked.  Increasing the reaction time and concentration of dNTPs resulted in low levels 
of extension past CCIQ, but given the extreme conditions for the reaction, it is believed 
that CCIQ is a serve block to replication with Dpo4 (Appendix A).  
 As noted earlier, an Ames assay showed CCIQ to be much less mutagenic than 
IQ.
4
  Our studies suggest the C8-CCIQ adduct is a strong block for replication for both 
Kf¯, pol II¯, and Dpo4.  Thus, the lack of revertents observed in the Ames assay could be 
due to lethality rather than a lack of mutagenicity. 
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CHAPTER III 
 
1,N
2
-DEOXYGUANOSINE ADDUCTS 
 
Part A: Introduction 
Another DNA adduct of interest is γ-hydroxy-1,N2-propano-2’-deoxyguanosine 
(γ- HOPdG, 3), which is formed from both endogenous and exogenous sources.  The 
source for this adduct is the α,β-unsaturated aldehyde acrolein.  Acrolein is believed to be 
produced endogenously through lipid peroxidation.
1,2
  Biological studies of acrolein in 
human cells showed that it causes mutations and has tumor-initiating activity.
3,4 
In previous in vitro DNA polymerase assays, 3 was studied with the human DNA 
polymerases η, ι, and κ, but not in frameshift prone DNA sequences.5,6  In these previous 
studies, pol η was shown to incorporate the correct base C opposite 3.  Additionally, 
when extension assays were performed with a primer that was recessed by nine bases, it 
was shown that pol η could incorporate opposite 3 as well as extend past it.5  It was 
shown that pol ι was able to incorporate the correct base C and the incorrect base T 
opposite 3.  However, pol ι was not able to further extend past 3.  Pol κ, on the other hand, 
was not able to incorporate a nucleotide opposite 3.  When the study was performed with 
a combination of pols ι and κ, insertion opposite the adduct and extension was observed.6 
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Figure 13: Adducts of Acrolein and Crotonaldehyde 
 
Two adducts that are closely related to 3 are the isomers of crotonaldehyde, R- 
and S-α-CH3-γ-OH-1,N
2
-propano-2’-deoxyguanosine (4a and 4b).  This α,β-unsaturated 
aldehyde has been shown to induce tumors in rodent livers and in human lymphoblasts.
7,8
  
Like 3, 4a and 4b can result from exogenous and endogenous sources.  Lipid 
peroxidation is a likely endogenous source for 3, while exogenous sources can be tobacco 
smoke and N-nitrosopyrrolidine.
9-10
  While these two adducts have not been studied with 
regards to in vitro DNA polymerase assays, the related adducts of 4-hydroxynonenal 
(HNE), 11R and 11S-trans-4-hydroxy-2-nonenal adducts of dG (5a and 5b), have been 
examined.
 11
 
The DNA polymerase extension assay studies of 5a and 5b were done with pol ι 
and pol κ, and the results were similar to 3.  The first nucleotide extension studies with a 
recessed primer showed that pol ι is able to incorporate opposite both isomers but is not 
able to extend past the adducts.  Unlike pol ι, pol κ was not able to incorporate a dNTP 
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opposite the adducts.  For a second set of studies, the primer was not recessed, but had a 
C opposite the adduct.  In this case pol ι could not extend past the adduct for either of the 
isomers.  However, pol κ was able to extend from a primer terminus in which C was 
paired opposite adducts 5a and 5b  with reasonable efficiency; although, it could not 
insert a dNTP opposite the adduct.
12
 
The interest of our research is twofold.  The first goal is to study the effects of 
specific adducts on the replication of DNA by Y-family polymerases.  The second goal is 
to study these adducts in frameshift prone sequences.  These studies were done through in 
vitro DNA polymerase extension assays.  The adducts were conducted as previous 
studies, i.e. 3, 4a, and 4b were studied with pol η, pol ι, and pol κ.  Through these studies 
we were able to indicated compounds which may be frameshift inducers. 
 
Part B: Experimental 
Unless otherwise noted, all commercially available chemicals were used as 
received.  MADLI-TOF mass spectrometry was performed at the Vanderbilt University 
Mass Spectrometry Resource Center.  A 3-hydroxypicolinic acid (HPA) matrix was used, 
and ammonium hydrogen citrate (7 mg/mL) was added to suppress sodium and potassium 
adducts.  Purified enzymes pol η, pol ι, and pol κ were purchased from Enzymax.  dNTP 
solutions (100mM) were purchased from New England BioLabs.  [γ-32P]ATP was 
purchased from Perkin-Elmer (NEN).  The unmodified oligonucleotides and primer 
nucleotides were purchased from Midland Certified Reagents.  All synthesized 
oligonucleotides and their purification were prepared by Dr. Ivan Kozekov and Albena 
Kozekova. 
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Synthesis of Oligonucleotides: An Expedite 8909 DNA synthesizer (PerSeptive 
Biosystems) was used to synthesize the adducted oligonucleotides on a 1 μmol scale, 
using the Ultramild line of phosphoramidites (phenoxyacetyl-protected dA, 4-isopropyl-
phenoxyacetyl-protected dG, acetyl-protected dC, and T phosphoramidites).  The solid 
supports were purchased from Glen Research.  The manufacturer’s standard synthesis 
protocol was used.
13,14
   
High Performance Liquid Chromatography (HPLC): Analyses and 
purification were performed using a Waters HPLC with a dual UV wavelength detector 
(Model 2487) that monitored at a wavelength of 254 nm.  The software used with the 
HPLC was Empower 1.  The oligonucleotides were purified with a 0.1M ammonium 
formate buffer at pH 3.5 (Solvent 1) and acetonitrile (Solvent 2).  The gradient was 
initially at 1% solvent 2 and was then linearly increased over 15 min to 8% solvent 2.  
The gradient was isocratic for 10 min at 8% solvent 2; after which time the gradient was 
increased to 99% solvent 2 over a period of 2 min.  The gradient was then isocratic for 3 
min at 99% solvent 2.  The gradient was decreased to 1% solvent 2 over a period of 2 min 
and isocratic for the final 3 min at 1% solvent 2. 
Capillary Gel Electrophoresis (CGE): Analyses of the purified oligonucleotides 
were carried out on a Beckman P/ACE Instrument System 5500 Series, in which the 
oligonucleotide was monitored at a wavelength of 260 nm.  The capillaries used with the 
P/ACE MDQ instrument were 31.2 cm x 100 μm eCAP.  The samples were applied at 10 
kV and were allowed to run at 9 kV.  The manufacturer’s 100-R gel (for ss DNA) was 
used to pack the column using a Tris-borate buffer with 7.0 M urea.  Modified 
oligonucleotides were found to be of  >95% purity. 
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Synthesis of 5’-d(CCCGGGG-Gγ-HOPdG-AAGCCTGCTCATGAGCCCCC )-3’ 
Oligonucleotide was purified using the Method II given above to yield 9.3 μmol.  
MALDI-TOF MS (HPA): m/z calcd for (M-H) 8588.4, found 8588.6 
    Synthesis of 5’-d(CCCGGGG-GR-croto-AAGCCTGCTCATGAGCCCCC)-3’ 
Oligonucleotide was purified using the method given above to yield 22.2 μmol.  MALDI-
TOF MS (HPA): m/z calcd for (M-H) 8602.4, found 8603.0 
    Synthesis of 5’-d(CCCGGGG-GS-croto-AAGCCTGCTCATGAGCCCCC)-3’ 
Oligonucleotide was purified using the method given above to yield 21.2 μmol.  MALDI-
TOF MS (HPA): m/z calcd for (M-H) 8602.4, found 8603.3 
Labeling and Annealing of Oligonucleotides: The given primer was labeled at 
the 5’-end by T4 polynucleotide kinase (T4PNK) and T4PNK buffer, which were 
obtained from New England BioLabs, using [γ-32P]ATP.  A concentration 0.5 nmol of 
primer was used with 2.5 μL of T4PNK buffer (10x concentration) and 20 units of the 
T4PNK enzyme.  [γ-32P]ATP, with 6.25 μL, was added and the volume adjusted to 8.85 
μL with water.  The reaction was allowed to react for one hour at 37 °C and then stopped 
by placing the reaction in a 95 °C bath for 10 min.  The reaction was purified on a 
Biospin column (BioRad).  Annealing of the template (adducted or unadducted) and 
primer, using a 1:1 molar ratio, was carried out with 50 mM Tris-HCl buffer (pH 7.8) by 
heating for 2 min at 95 °C and then allowing to slowly cool to 30 °C. 
Single Nucleotide Incorporation Assays: The 
32
P-labeled oligonucleotides, that 
have been annealed, were extended in the presence of single dNTPs.  The dNTPs (2 μL) 
were added to preincubated enzyme/DNA mixtures which brought the total amount of 
solution to 10 μL.  The final concentrations for the assays with pol η, κ, and ι were: 25 
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mM Tris-HCl, pH 7.8, 10 nM DNA duplex, 4 nM enzyme, 5 mM DTT, 0.1 mg mL
-1
 
BSA, and 5 mM MgCl2.  Pol η, κ, and ι were allowed to react for 30 min at ambient 
temperature.  The reactions were quenched by 20 μL of a 20 mM EDTA in 95% 
formamide (v/v) containing bromophenol blue and heated for 10 min at 95°C.  
Electrophoresis was used to separate aliquots (5-8 μL) of the reaction on a denaturing gel 
containing: 8.0 M urea, 16% acrylamide (w/v) (from 19:1 Acrylamide/Bisacrylamide 
Stabilized Solution, AccuGel, National Diagnostics), and 80 mM Tri borate buffer, pH 
7.8, with 1 mM EDTA.  A PhosphorImager screen (Imaging Screen K, Bio-Rad) was 
exposed to the gel for a minimum of 6 hours.  The screen was imaged using a 
PhosphorImaging system (Bio-Rad, Personal Molecular Imager) and the manufacturer’s 
Quantity One software, version 4.6.3. 
Full-length Extension Assay: The 
32
P-labeled oligonucleotides (after annealing) 
were extended in the presence of all four dNTPs.  The dNTPs (2 μL) were added to 
preincubated enzyme/DNA mixtures which brought the total amount of solution to 10 μL.  
The final concentrations for the assays with pol η, κ, and ι were: 25 mM Tris-HCl, pH 7.8, 
10 nM DNA duplex, 4 nM enzyme, 5 mM DTT, 0.1 mg mL
-1
 BSA, and 5 mM MgCl2.  
Pol η, κ, ι, and a mixture of pol κ and ι were allowed to react for 30 min at ambient 
temperature.  The reactions were quenched by 20 μL of a 20 mM EDTA in 95% 
formamide (v/v) containing bromophenol blue and heated for 10 min at 95°C.  
Electrophoresis was used to separate aliquots (5-8 μL) of the reaction on a denaturing gel 
containing: 8.0 M urea, 16% acrylamide (w/v) (from 19:1 Acrylamide/Bisacrylamide 
Stabilized Solution, AccuGel, National Diagnostics), and 80 mM Tri borate buffer, pH 
7.8, with 1 mM EDTA.  A PhosphorImager screen (Imaging Screen K, Bio-Rad) was 
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exposed to the gel for a minimum of 6 hours.  The screen was imaged using a 
PhosphorImaging system (Bio-Rad, Personal Molecular Imager) and the manufacturer’s 
Quantity One software, version 4.6.3. 
Sequencing of Full-Length Extension:  The full-length extension assays were 
performed at 37 °C with 25mM Tris-HCl, pH 7.8, 100 nM DNA duplex with a biotinated 
primer, 40 nM enzyme, 5 mM DTT, 0.1 µg mL
-1
 BSA, 5 mM MgCl2, and 50 µM of each 
dNTP.  The enzymes used were pol ι, pol κ, and a combination of pol ι and κ.  The 
reaction was allowed to run overnight, then 0.5 mL of Streptavidin Sepharose™ beads, 
(GE Healthcare) which had been centrifuged and washed subsequently with phosphate 
buffer (2 x 500 µL), was added and rinsed with phosphate buffer (3 x 200 µL). The 
resulting suspension was allowed to shake for 2 hours in a rotation shaker. The beads 
were then washed with water (2 x 400 µL).  Hydrolysis by UDG was completed in a 500 
µL solution at 37 °C with 20 units UDG, 50 mM Tris-HCl, 1mM EDTA, and 1 mM DTT 
for 4 hours.  The beads were then washed with water (2 x 400 µL).  The DNA is 
hydrolyzed using 0.25 M piperidine in a 95 °C bath for 1 hour. The liquid was collected 
and the beads were washed with water (2 x 350 µL).  All fractions were combined, 
filtered, and lyophilized.  The resulting product was dissolved in water (60 µL).  A 
mixture of 20 µL of the solution and 0.007 A260 of 5’-pTG TGT GTG G, which is used 
as an internal standard, were used for MS analysis on a Waters Acquity UPLC contected 
to a Finnigan LTQ mass spectrometer with an Acquity UPLC C18 column at the 
Vanderbilt University Mass Spectrometry Research Center.  The UPLC conditions 
started with the column being warmed to 55 °C and consisted of Solvent 1, 10 mM 
NH4CH3CO2 in 2% CH3CN, and Solvent 2, 10 mM NH4CH3CO2 in 95% CH3CN, with a 
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gradient initially at 0% for Solvent 2, with a flow rate of 150 µL.  The gradient for 
Solvent 2 increased to 3% over 3 minutes, at which time the gradient became linear for 
1.5 minutes in order to reach 20%.  Solvent 2 was then increased to 100% in 0.5 minutes 
and then isocractic for Solvent 2 for 0.5 minutes.  The gradient was then reduced to 0% 
of Solvent 2 in 1 minute, at which time Solvent 2 was isocratic for 3 minutes.  The 
samples were injected by an auto-sampler.  The conditions for the LTQ consisted of the 
source voltage at 4 kV, source current 100 µA, auxiliary gas flow at 20, sweep gas flow 
at 5, sheath gas flow at 34, capillary voltage at -49 V, cappilarry temperature at 350 °C, 
and tube lens voltage at -90 V.  The MS/MS conditions consisted of normalized collision 
energy at 35%, activation Q 0.250, and activation time of 30 ms.  The product ion spectra 
were acquired for a range of 345-2000 m/z.  The ions chosen for MS/MS went through a 
CID analysis and the CID products that showed promise for being an oligonucleotide 
sequence were compared to data from the Mono Oligo Mass Calculator, Mass 
Spectrometry Group of Medicinal Chemistry at the University of Utah 
(http://library.med/utah.edu/masspec).   
 
Part C: Results and Discussion 
 
Section I: Polymerase By-pass Assays 
Four different oligonucleotides were synthesized, one each containing the dG 
adducts of acrolein, R-crotonaldehyde, S-crotonaldehyde, and one with no modified base.  
The adducts were incorporated at the beginning of a reiterated sequence of four G’s.  The 
template was then annealed to the corresponding -1 primer for single nucleotide 
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incorporation or a -4 primer for full-length extension assays.  The primer strands were 
then labeled at the 5’-end with 32P.  Single nucleotide incorporation and extension 
reactions were then examined using the human DNA polymerases η, κ, and ι. 
 
Polymerase η 
The single nucleotide incorporation of a reiterated sequence of G’s produces an 
extended product (Figure 14).  While for the most part dATP, dTTP, and dGTP were 
incorporated opposite the adducts, likely due to high concentration of dNTP.  All adducts 
allowed for some incorporation and extension, but not as efficiently as the unmodified 
oligonucleotide.  Of the three adducts studied, the acrolein and R-crotonaldehyde adducts 
showed considerably better incorporation efficiency than the S-crotonaldehyde adduct 
(Figure 14: 1b, 1c, 1d).  Of note is that the adducts showed a +1 extension, but because 
the unmodified oligonucleotide gave this same product (Figure 14: 1a), the result is 
likely to be from a blunt end insertion at the end of the sequence. 
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Figure 14: Single Nucleotide Incorporation by Pol η 
 
Pol η and all four dNTPs were used for full-length extension reactions.  Pol η was 
able to complete the extension past the acrolein adduct (Figure 15: 1b).  The fully 
extended insertion product was a +1 product; while this could be interpreted as a 
frameshift insertion, examination of the unmodified oligonucleotide also showed a +1 
extension product (Figure 15: 1a), indicating that an insertion is not likely and probably 
the result of blunt end insertion.  Pause sites were observed for the R isomer of 
crotonaldehyde up to the adduct site (Figure 15: 1c).  However, pol η was able to bypass 
and extend to a +1 product.  Again, this would not seem to be a frameshift insertion due 
to the unmodified oligonucleotide being extended to the same length product.  The S-
Crotonaldehyde adduct appeared to be the most significant block of the three adducts 
studied to replication by pol η (Figure 15: 1d).  The +1 extension product was less 
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visible with the S-crotonaldehyde adduct than by the other adducts, although full-length 
products could be observed.  
 
 
 
Figure 15: Nucleotide Extension by Pol η with All Four dNTPs 
 
Polymerase Kappa 
As with pol η, pol κ was able to incorporate multiple dCTPs with the unmodified 
oligonucleotide, albeit with reduced efficiency (Figure 16: 1a).  This same incorporation 
was observed up to the G5 position with the acrolein adduct (Figure 16: 1b), with similar 
efficiency as the unmodified.   The R-crotonaldehyde adduct mis-incorporated a dGTP 
opposite the adduct (Figure 16: 1c), but no incorporation of dCTP was seen.  Insertion of 
dGTP was observed opposite the S-crotonaldehyde adduct, but at a drastically reduced 
efficiency as compared to the R-crotonaldehyde adduct, and there was no dCTP 
incorporation (Figure 16: 1d). 
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Figure 16: Single Nucleotide Incorporation by Pol κ 
 
  Pol κ appeared to be less efficient than pol η at extension (Figure 17).  
Specifically, the unmodified oligonucleotide required a higher concentration of dNTP in 
order to reach the fully extended product (Figure 17: 1a).  When pol κ was used to 
replicate past the acrolein adduct, the adduct was a significant block to full extension, 
although a -1 extension product was observed, which may suggest a possible one base 
deletion product (Figure 17: 1b).  Extension past the R-crotonaldehyde adduct appeared 
also to be very inefficient with pol κ (Figure 17: 1c).  Pol κ was able to insert opposite 
the adduct at higher dNTP concentrations, but further extension was inefficient.  Even at 
the high dNTP  concentration further extension was largely inhibited, and only low levels 
of fully extended products were observed (Figure 17: 1d).  With the S isomer of the 
crotonaldehyde adduct, Pol κ was severly blocked.  The polymerase was only able to 
incorporate opposite the adduct but not extend, even at high concentration of dNTP.   
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Figure 17: Nucleotide Extension by Pol κ with All Four dNTPs 
 
Polymerase Iota 
Pol ι is known to be an inefficient polymerase, but one that can incorporate a 
dNTP opposite a myriad of adducts (Figure 18: 1a).  In the unmodified sequence, pol ι 
was able to extend the full G repeat sequence.  The acrolein adduct showed that pol ι was 
only able to extend to the G5 position, but a considerable amount of product remained 
with just one dCTP incorporated (Figure 18: 1b).  In regards to the crotonaldehyde 
adducts, pol ι was not able to extend past either adduct, but did incorporate dCTP and 
dTTP opposite the adduct (Figure 18: 1c, 1d).  This is not surprising given that studies 
have shown pol ι to work in tandem with pol κ, where pol ι incorporates opposite the 
adduct and pol κ extends past it.  As for the mis-incorporation, we know that pol ι has a 
higher mis-incorporation rates in which dTTP is incorporated with almost equal 
efficiency as dCTP.  
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Figure 18: Single Nucleotide Incorporation by Pol ι 
 
 In the unmodified oligonucleotide, it is not a surprise that this polymerase 
struggles to reach the fully extended product (Figure 19: 1a).  As stated earlier, pol ι is 
known for its ability to incorporate opposite a wide range of adducts, thus while all three 
adducts were blocks to some extent, incorporation opposite the adducts was still achieved 
(Figured 1b, 1c, 1d).  These results are in accord with the results obtained from the 
single nucleotide incorporation results. 
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Figure 19: Nucleotide Extension by Pol ι with All Four dNTPs 
 
Polymerases Iota and Kappa 
 As noted earlier, it has been observed that pol ι and κ can work together to bypass 
and extend damaged DNA.  We observed that pol ι can incorporate opposite all three of 
our adducts and then pol κ can complete the extension.  Given this, nucleotide extension 
reactions were examined with equal concentrations of pol ι and κ present (Figured 20).  
As expected, the results suggest that the bypass and extension of the adducts are slightly 
more efficient, but this must be confirmed with quantification.  This could be the result of 
the polymerases handing off replication, thus requiring more time to complete the full 
length replication. 
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Figure 20: Nucleotide Extension by Pol ι and κ 
 
Section II: Polymerase By-pass Sequencing 
Four different oligonucleotides were synthesized, containing the acrolein , R-
crotonaldehyde, and S-crotonaldehyde adducts of dG, and an unmodified dG.  The 
adducts were inserted at the prior to a reiterated sequence of four G’s.  After the 
oligonucleotides were purified, they were annealed to a -1 complementary primer that 
contained a biotin unit at the 5’end, which allows for separation of the extended 
oligonucleotide.  A run of 10 T’s was used as a spacer between the biotin moiety and the 
primer sequence.  A schematic of the procedure is available in Figure 21.  The products 
greater than 5% relative intensity were considered for sequencing and quantification. 
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Figure 21: Extended Nucleotide Collection 
 
Polymerase η 
 The nucleotide extension reaction was completed using pol η and all four dNTPs 
in order to study the replication of the adducted oligonucleotide (Figure 22).  The major 
product from the extension of the unmodified oligonucleotide was a result of error free 
bypass and extension (Figure 23, m/z = 917) with the yield of 54%.  The peak at m/z= 
917.4 represents the [M-3H] ion. 
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Figure 22: MS of the Product from Pol η Extenstion (X = dG) 
 
 
 
Figure 23: MS/MS of m/z = 917 Product 
 
 When the acrolein adduct was examined (Figure 24), the major product resulted 
from error free extension with a 20% yield (m/z = 917).  Two products observed arose 
from misincorporation of dATP (m/z = 926) with 2.2% yield and the mis-incorporation of 
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dGTP (m/z = 931), in 3.2% yield; no frameshift products were observed with the acrolein 
adduct and pol η (Figure 25). 
 
 
 
Figure 24: MS of the Products from Pol η Extension (X = Acrolein) 
 
 
 
Figure 25: MS/MS of m/z 931 Product 
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 The R-crotonaldehyde adduct produced a more interesting array of products 
(Figure 26).  The error-free product was not the most abundant and was obtained, in only 
1.6% yield; the most abundant product observed (7.6% yield) resulted from a deletion of 
a G (5’-TA CCC GGG-3’, m/z= 829).  This deletion product resulted from the initial mis-
incorporation of dATP opposite the adduct followed by the deletion of a G to give a -1 
frameshift product.  An expected one-base deletion product was observed in our mass 
spectrum (m/z = 821) in 2% yield (Figure 27).  Two additional non-frameshift, but error-
prone products were observed in which dATP (m/z = 926) and dGTP (m/z = 931) were 
mis-incorporated in 0.9% and 3.0% yield, respectively. 
 
 
 
Figure 26: MS of the Products from Pol η Extension (X = R-Crotonaldehyde) 
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Figure 27: MS/MS of m/z 821 Product 
 
 The MS spectrum for the S-crotonaldehyde adduct and pol η revealed similar 
products as the R isomer, but the distribution of products was greater (Figure 28).  The 
three most abundant products from the extension reaction had roughly the same yield.  
These resulted from the correct incorporation of dCTP (m/z = 917) in 2.3%, the mis-
incorporation of dGTP (m/z = 931) in 3.0%, and a deletion of a G (m/z = 821) in 2.5% 
yield.  Another product that was observed was the mis-incorporation of dATP (m/z = 
925) followed by error-free extension with a 1.8% yield (Figure 29).  The S-
crotonaldehyde adduct produced a myriad of product types that were relatively evenly 
distributed, which is in contrast with the R-crotonaldehyde adduct. 
56 
 
 
 
Figure 28: MS of the Products from Pol η Extension (X = S-Crotonaldehyde) 
 
 
 
Figure 29: MS/MS of m/z 925 
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Polymerase κ 
 The extension reactions with pol κ afforded a simpler distribution of products than 
pol η (Figure 30).  The major product observed was the truncated oligonucleotide (m/z = 
808) in 25% yield (Figure 31).  This oligonucleotide is missing the last G, but this is not 
an uncommon extension product and is not seen as an error-prone product. The other 
observed product was the fully extended, error-free product (m/z = 917) in 2.8% yield.  
 
Figure 30: MS of the Products from Pol κ Extension (X = dG) 
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Figure 31: MS/MS of m/z 808 
 
 When the nucleotide extension reaction was examined with the acrolein adduct, 
four products were observed (Figure 32).  Those with error-free products are the 
truncated oligonucleotide (m/z = 808) and the fully extended oligonucleotide (m/z = 917), 
which totals to roughly 24% yield. The error-prone product resulted from the mis-
incorporation of dGTP followed by error-free extension.  The two products differed by 
the presence of the 3’-terminal G (m/z = 821 vs. 931, Figure 33).  
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Figure 32: MS of Products from Pol κ Extension (X = Acrolein) 
 
 
 
Figure 33: MS/MS of m/z 821 
 
 The R-crotonaldehyde adduct produced products that were difficult to elucidate 
the sequences (Figure 34).  The product in greatest abundance (19% yield) was the mis-
incorporation of dGTP followed by error-free extension, but missing the 3’-terminal G 
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(m/z = 821).  A related error-free product (m/z = 808) was observed at 2%.  The product 
with the second highest abundance (m/z = 931) in 2% yield was the fully extended 
sequence after a mis-incorporation of dGTP opposite the adduct.   
 
 
 
Figure 34: MS of Products from Pol κ Extension (X = R-Crotonaldehyde) 
 
 The pol κ extension of the S-crotonaldehyde adduct had four products that were 
identifiable (Figure 35).  The most abundant product, which accounted for 9% yield, 
resulted from error-free bypass and extension (m/z 808 and 917) and differed by the 
presence of the 3’-terminal G.  The second most abundant product resulted from mis-
incorporation of dGTP (m/z = 821) and accounted for 6%.  The -1 frameshift product 
(711) was observed at 4% yield (Figure 36). 
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Figure 35: MS of Products from Pol κ Extension (S-Crotonaldehyde) 
 
 
 
Figure 36: MS/MS of m/z 711 
 
Polymerases ι and κ 
 As noted previously, pol ι and κ has been observed to work sequentially to bypass 
and extend past a DNA adduct.  We observed that pol ι had considerable difficulty 
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replicating past our adducts; we therefore decided to examine the bypass with pol ι and κ.  
The first oligonucleotide examined was the unadducted sequence (Figure 37). The two 
most abundant products resulted from error-free replication and differed by the presence 
of a 3’-terminal G.  Together both oligonucleotides (m/z = 808 and 917) account for a 
25% yield. The third product (m/z = 904) was not identified.  Not surprisingly this 
potential collaboration between these polymerases worked well for the unadducted 
template oligonucleotide. 
 
 
 
Figure 37: MS of Products from Pol ι+κ Extension (X = dG) 
 
 On the other hand, more products were observed when the acrolein adduct was 
replicated by the combination of pol κ and ι (Figure 38).  As seen with the unadducted 
oligonucleotide, error free products at m/z = 808 and 918 accounted for 7% yield.  The 
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most abundant product observed was the misincorporation of dCTP at the 3’-end of the 
sequence (m/z = 904) at 4 %.  None of the products identified resulted from a frameshift.  
 
 
Figure 38: MS of Products from Pol ι+κ Extension (X = Acrolein) 
 
 We next looked at the R isomer of the crotonaldehyde adduct and saw a wider 
distribution of products when compared to the acrolein adduct (Figure 39).  A frameshift 
product was observed (m/z = 821).  The frameshift product could not be quantified 
because a truncated mis-incorporation of dG was also present.  The UPLC column was 
unable to separate both products with the m/z of 821, thus inhibiting the quantification of 
the two products.  Other products that were observed result from error-free bypass and 
extension (m/z 808 and 918) in roughly 2% yield.  In lesser yield was a product arising 
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from a misincorporation dCTP at the 3’-end of the oligonucleotide (m/z = 904) in 0.5% 
yield (Figure 40). 
 
 
 
Figure 39: MS of Products from Pol ι+κ Extension (X = R-Crotonaldehyde) 
 
 
 
Figure 40: MS/MS of m/z 904 
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 Finally, the S isomer of the crotonaldehyde adduct was examined (Figure 41).  
We found the error-free products at m/z = 808 and 904 accounted for almost 3% yield. 
Additionally, the -1 frameshift products (m/z = 711 and 821) were observed in roughly 
4% combined yield and includes a product with a truncated 3’-end (m/z = 711), and the 
fully extended frameshift oligonucleotide (m/z = 821).  
 
 
 
Figure 41: MS of Product from Pol ι+κ Extension (X = S-Crotonaldehyde) 
 
Part D: Conclusion 
 The γ-HOPdG adduct derived from acrolein and the two isomers of the 
crotonaldehyde adduct, R- and S-α-CH3-γ-OH-1,N
2
-propano-2’-deoxyguanosine, were 
examined in a frameshift prone reiterated sequence of G’s.  Replication studies were then 
carried out with recessed primers using both single nucleotide incorporation and full-
length extension reactions with human Y-family DNA polymerases. Full-length 
extension products were then identified using tandem mass spectroscopy.  
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 Single nucleotide incorporation resulted in multiple incorporations of dCTPs, 
which is not surprising given that the template was a reiterated G sequence.  With pol η, 
both the acrolein and R-crotonaldehyde adducts were able to incorporate the same dNTPs 
as the unmodified sequence.  The S-crotonaldehyde adduct was a stronger block in the 
single nucleotide incorporation and extension assays.  Pol κ yielded different 
incorporation results, with mis-incorporation of dGTP observed with the R-
crotonaldehyde adduct, but extension past the mis-incorporation was interested.  The S-
crotonaldehyde adducts was a strong block to full-length extension.  With pol ι, we 
observed that extension was inefficient. This is in agreement with other studies that have 
shown pol ι to be an excellent polymerase for incorporation opposite an adduct.6  
 Full-length extension of the templates was completed with all four dNTPs present.  
Pol η was able to replicate past all adducts, but with a wide range of efficiencies.  This is 
evident by the reduction in extended products seen from the most efficient, dG, to the 
least efficient, the S-crotonaldehyde adduct. When pol κ was examined we found similar 
results to that of pol η, in that the extension products were observed but that the yield was 
reduced further by each subsequent adduct, with the S-crotonaldehyde adduct having the 
greatest ability to block replication.  Even though pol ι was observed to inhibit extension 
of the template from the single nucleotide experiment, the nucleotide extension reactions 
were examined.  As indicated in the single nucleotide experiment, pol ι is able to insert 
opposite the adducts, but extension past the adducts is inhibited.  As noted early, it has 
been shown that pol ι and κ can work in tandem to replicate through adducted bases; 
nucleotide extension was therefore examined with both pol ι and pol κ.  Minimal 
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extension was seen with this combination of polymerases; however, extension products 
were observed.   
Extension assays are extremely useful in determining an adduct’s effect on a 
polymerase for replication, but the results give us little information on the actual products 
formed.  Because of this, identification of the extension products is desirable.  This was 
accomplished using a modified primer with biotin, uracil, and 10 T’s.  Once the extended 
products were isolated, MS and MS/MS were used to identify and quantify the extension 
products.  Our quantification of the products confirmed our extension assays where the 
unmodified oligonucleotides gave higher yields of product formation the adducted 
templates.  The total yield for bypass extension was highest for the acrolein adduct, and 
lowest for the S-crotonaldehyde adduct.  When the sequences of the extension products 
were determined, the acrolein adduct was found not to induce a deletion with any of the 
polymerases examined.  Replication of the R-crotonaldehyde adduct by pol η resulted in 
a majority of frameshift products with 66% of the products having been either a mis-
incorporation of dATP or correct incorporation of dCTP followed by a -1 frameshift.  No 
frameshift products were observed with pol κ and the frameshift product could not be 
determined for the combination of pol ι and κ.  For the S-crotonaldehyde adduct, the 
combination of pol ι and κ produced the greatest percentage of frameshift products with 
54% of the products being the truncated and full frameshift product.  Pol η and pol κ had 
roughly the same percentage of frameshift products, pol η producing 26% of the full 
frameshift product and pol κ producing 24% of the truncated frameshift product.  Again, 
it must be stressed that the actual yield of these products were low, having no greater than 
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7.6% chemical yield, and were in line with our nucleotide extension assays but that the 
percentage of the products was significant.   
 In these sets of experiments we were able to show the difference in the 
polymerases’ ability to incorporate and extend past three different adducts.  Frameshift 
products were seen, but only with the two isomers of the crotonaldehyde adduct and not 
the acrolein adduct.  Since the two isomers had differences in their ability to induce and 
type of frameshift mutations, NMR studies of the adduct in our sequence will hopeful 
indicate the role the stereochemistry of the isomers have on nucleotide pairing. The 
sequences of the extension products were determined by a method developed in our lab.  
This procedure has opened a new avenue to studying and indentifying frameshift inducers 
in oligonucleotides.  
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Appendix A: 
Polymerase Assay for Chapter II 
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Nucleotide Extension of the G3 Position with Increased dNTP and Time 
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Appendix B: 
MS/ MS for Chapter III 
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MS/MS of m/z 829 Product 
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MS/MS of m/z 821 Products 
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Appendix C: 
Concentration Curves for Chapter III 
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Concentration Curve for Extension Product m/z 711 
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Concentration Curve for Extension Product m/z 808 
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Concentration Curve for Extension Product m/z 821 
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Concentration Curve for Extension Product m/z 821 
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Concentration Curve for Extension Product m/z 829 
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Concentration Curve for Extension Product m/z 904 
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Concentration Curve for Extension Product m/z 917 
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Concentration Curve for Extension Product m/z 925 
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Concentration Curve for Extension Product m/z 931 
